Injectable human recombinant collagen matrices limit adverse remodeling and improve cardiac function after myocardial infarctionSarah McLaughlin, Emilio I. Alarcón, Richard J. Seymour et al.|Nature Communications|2019Cited by 155
Timing underpins the benefits associated with injectable collagen biomaterial therapy for the treatment of myocardial infarctionNick J. R. Blackburn, Erik J. Suuronen, Tanja Sofrenovic et al.|Biomaterials|2014Cited by 101
The role of integrin α2 in cell and matrix therapy that improves perfusion, viability and function of infarcted myocardiumAli Ahmadi, Erik J. Suuronen, Brian McNeill et al.|Biomaterials|2014Cited by 39
Collagen biomaterial stimulates the production of extracellular vesicles containing microRNA‐21 and enhances the proangiogenic function of CD34 <sup>+</sup> cellsBrian McNeill, Erik J. Suuronen, Aleksandra Ostojic et al.|The FASEB Journal|2018Cited by 24
Time of Delivery Influences the Efficacy of Collagen Matrix Therapy for Myocardial InfarctionN.J. Blackburn, Erik J. Suuronen, Tanja Sofrenovic et al.|Canadian Journal of Cardiology|2013Cited by 0